Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients ...

Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will participate in a fireside chat ...

Results were announced from a phase 3 trial evaluating solriamfetol for major depressive disorder with/without severe excessive daytime sleepiness.

As thousands of people await a lifesaving heart, scientists are racing to buy them more time. A promising advance from scientists in Germany offers a potential solution.

New research highlights that frailty in patients with RA — young and old — raises infection risk and complicates treatment, calling for earlier detection and tailored care.